Clinical effectiveness and cost-effectiveness of target therapies for adult patients with locally advanced or metastatic non-small cell lung cancer: A systematic review

Research output: Contribution to journalReview article

Abstract

Treatment for advanced non-small cell lung cancer has changed in the last two decades, with many new drugs, mostly target agents, included in the algorithm, improvement of progression free survival and overall survival, but also higher costs for health systems or health insurances. Herein, we analyze the clinical effectiveness of target therapies for non-small cell lung cancer, according to their clinically meaningful outcome criteria and their cost impact.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalCurrent Cancer Drug Targets
Volume18
Issue number5
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • Chemotherapy
  • Cost
  • Metastases
  • NSCLC
  • Prognoses
  • Target agents
  • Therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical effectiveness and cost-effectiveness of target therapies for adult patients with locally advanced or metastatic non-small cell lung cancer: A systematic review'. Together they form a unique fingerprint.

  • Cite this